Derick G Wansink

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/5637438/publications.pdf

Version: 2024-02-01

		623734	526287
28	890	14	27
papers	citations	h-index	g-index

30	30	30	954
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Imaging of CPP Delivery Mechanisms of Oligonucleotides. Methods in Molecular Biology, 2022, 2383, 197-210.	0.9	2
2	A comprehensive atlas of fetal splicing patterns in the brain of adult myotonic dystrophy type 1 patients. NAR Genomics and Bioinformatics, 2022, 4, lqac016.	3.2	2
3	Systemic cell therapy for muscular dystrophies. Stem Cell Reviews and Reports, 2021, 17, 878-899.	3.8	11
4	248th ENMC International Workshop: Myotonic dystrophies: Molecular approaches for clinical purposes, framing a European molecular research network, Hoofddorp, the Netherlands, 11â€“13 October 2019. Neuromuscular Disorders, 2020, 30, 521-531.	0.6	1
5	Advanced Fluorescence Imaging to Distinguish Between Intracellular Fractions of Antisense Oligonucleotides. Methods in Molecular Biology, 2020, 2063, 119-138.	0.9	3
6	In Vitro Synthesis and RNA Structure Probing of CUG Triplet Repeat RNA. Methods in Molecular Biology, 2020, 2056, 187-202.	0.9	0
7	The nuclear concentration required for antisense oligonucleotide activity in myotonic dystrophy cells. FASEB Journal, 2019, 33, 11314-11325.	0.5	14
8	CRISPR/Cas Applications in Myotonic Dystrophy: Expanding Opportunities. International Journal of Molecular Sciences, 2019, 20, 3689.	4.1	24
9	Expanded CUG repeats in DMPK transcripts adopt diverse hairpin conformations without influencing the structure of the flanking sequences. Rna, 2019, 25, 481-495.	3.5	15
10	Certainty-based marking in a formative assessment improves student course appreciation but not summative examination scores. BMC Medical Education, 2019, 19, 178.	2.4	6
11	(CTG)n repeat-mediated dysregulation of MBNL1 and MBNL2 expression during myogenesis in DM1 occurs already at the myoblast stage. PLoS ONE, 2019, 14, e0217317.	2.5	12
12	Recovery in the Myogenic Program of Congenital Myotonic Dystrophy Myoblasts after Excision of the Expanded (CTG)n Repeat. International Journal of Molecular Sciences, 2019, 20, 5685.	4.1	14
13	Assisted delivery of antisense therapeutics in animal models of heritable neurodegenerative and neuromuscular disorders: a systematic review and meta-analysis. Scientific Reports, 2018, 8, 4181.	3.3	9
14	Abnormalities in Skeletal Muscle Myogenesis, Growth, and Regeneration in Myotonic Dystrophy. Frontiers in Neurology, 2018, 9, 368.	2.4	51
15	Antisense transcription of the myotonic dystrophy locus yields low-abundant RNAs with and without (CAG)n repeat. RNA Biology, 2017, 14, 1374-1388.	3.1	25
16	CRISPR/Cas9-Induced (CTGâ‹…CAG) n Repeat Instability in the Myotonic Dystrophy Type 1 Locus: Implications for Therapeutic Genome Editing. Molecular Therapy, 2017, 25, 24-43.	8.2	108
17	Trinucleotide-repeat expanded and normal DMPK transcripts contain unusually long poly(A) tails despite differential nuclear residence. Biochimica Et Biophysica Acta - Gene Regulatory Mechanisms, 2017, 1860, 740-749.	1.9	7
18	Intracellular Distribution and Nuclear Activity of Antisense Oligonucleotides After Unassisted Uptake in Myoblasts and Differentiated MyotubesIn Vitro. Nucleic Acid Therapeutics, 2017, 27, 144-158.	3.6	15

#	Article	IF	Citations
19	A low absolute number of expanded transcripts is involved in myotonic dystrophy type 1 manifestation in muscle. Human Molecular Genetics, 2016, 25, 1648-1662.	2.9	31
20	Cell Membrane Integrity in Myotonic Dystrophy Type 1: Implications for Therapy. PLoS ONE, 2015, 10, e0121556.	2.5	21
21	Design and Analysis of Effects of Triplet Repeat Oligonucleotides in Cell Models for Myotonic Dystrophy. Molecular Therapy - Nucleic Acids, 2013, 2, e81.	5.1	42
22	Abnormal actomyosin assembly in proliferating and differentiating myoblasts upon expression of a cytosolic DMPK isoform. Biochimica Et Biophysica Acta - Molecular Cell Research, 2011, 1813, 867-877.	4.1	14
23	DMPK protein isoforms are differentially expressed in myogenic and neural cell lineages. Muscle and Nerve, 2009, 40, 545-555.	2.2	19
24	Triplet-repeat oligonucleotide-mediated reversal of RNA toxicity in myotonic dystrophy. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 13915-13920.	7.1	245
25	A Tail-Anchored Myotonic Dystrophy Protein Kinase Isoform Induces Perinuclear Clustering of Mitochondria, Autophagy, and Apoptosis. PLoS ONE, 2009, 4, e8024.	2.5	22
26	Transgenic overexpression of human DMPK accumulates into hypertrophic cardiomyopathy, myotonic myopathy and hypotension traits of myotonic dystrophy. Human Molecular Genetics, 2004, 13, 2505-2518.	2.9	55
27	Alternative Splicing Controls Myotonic Dystrophy Protein Kinase Structure, Enzymatic Activity, and Subcellular Localization. Molecular and Cellular Biology, 2003, 23, 5489-5501.	2.3	54
28	Constitutive and regulated modes of splicing produce six major myotonic dystrophy protein kinase (DMPK) isoforms with distinct properties. Human Molecular Genetics, 2000, 9, 605-616.	2.9	60